| Half-life | 12 hours |
| Tmax | 6 h |
| Bioavailability | 50 % (approx) |
| Protein Binding | 95 % |
| Volume of Distribution | 164 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Contraindicated in hepatic failure; avoid with substantial alcohol use; metabolism via CYP1A2 and CYP2D6. |
Severity: Moderate
Adverse Effects:
Nausea, dry mouth, constipation, insomnia, sexual dysfunction, increased sweating, hepatotoxicity risk
Contraindications:
Chronic liver disease, concomitant MAOI use
Precautions:
Monitor liver function; caution with alcohol; taper slowly to avoid withdrawal.